Current medicinal chemistry最新文献

筛选
英文 中文
Aptamers as a Potential Therapeutic and Screening Molecule for Oral Cancer. 适配体作为口腔癌潜在的治疗和筛选分子。
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-10 DOI: 10.2174/0109298673356297241208155602
Thangavel Lakshmipriya, Subash C B Gopinath, Dhamodharan Prabhu, Evan T Salim, Makram A Fakhri
{"title":"Aptamers as a Potential Therapeutic and Screening Molecule for Oral Cancer.","authors":"Thangavel Lakshmipriya, Subash C B Gopinath, Dhamodharan Prabhu, Evan T Salim, Makram A Fakhri","doi":"10.2174/0109298673356297241208155602","DOIUrl":"https://doi.org/10.2174/0109298673356297241208155602","url":null,"abstract":"","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Scenario in Associating Clinical COVID-19 Biomarkers for Developing Surveillance Platforms. 关联临床COVID-19生物标志物开发监测平台的现状
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-09 DOI: 10.2174/0109298673331044241031100627
Thangavel Lakshmipriya, Subash C B Gopinath, Yeng Chen, Sreenivasan Sasidharan, Sreeramanan Subramaniam, Ahmad Anas Nagoor Gunny, Umi Fazara Md Ali, M N Salimi, Makram A Fakhri, Evan T Salim, Theivasanthi Thirugnanasambandan
{"title":"Current Scenario in Associating Clinical COVID-19 Biomarkers for Developing Surveillance Platforms.","authors":"Thangavel Lakshmipriya, Subash C B Gopinath, Yeng Chen, Sreenivasan Sasidharan, Sreeramanan Subramaniam, Ahmad Anas Nagoor Gunny, Umi Fazara Md Ali, M N Salimi, Makram A Fakhri, Evan T Salim, Theivasanthi Thirugnanasambandan","doi":"10.2174/0109298673331044241031100627","DOIUrl":"https://doi.org/10.2174/0109298673331044241031100627","url":null,"abstract":"<p><p>The novel coronavirus that caused the epidemic and pandemic resulting in the acute respiratory illness known as coronavirus disease 2019 (COVID-19) has plagued the world. This is unlike other coronavirus outbreaks that have occurred in the past, such as Middle East respiratory syndrome (MERS) or severe acute respiratory syndrome (SARS). COVID-19 has spread more quickly and posed special challenges due to the lack of appropriate treatments and vaccines. Real-time polymerase chain reaction (RTPCR) and rapid antibody tests (surveillance tests) are the two most used tests (confirmation tests). However, the latter takes hours to complete, and the former may produce false positives. Scientists have invested significant effort to create a COVID-19 diagnostic system that is both highly sensitive and reasonably priced. Early detection of COVID-19 is a major area of focus for sensing devices based on nanomaterials. This overview enhanced insights into potential coronavirus biomarkers and, compared to earlier studies, introduced new avenues. Further, it covers the development of COVID-19 diagnostic systems from an analytical point of view, including clinical markers and their subsequent applications with biosensors.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design, Synthesis, Biological Evaluation and Docking Studies of 2-hydroxy-4-benzyloxy Chalcone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease. 2-羟基-4-苄基查尔酮衍生物治疗阿尔茨海默病多功能药物的设计、合成、生物学评价及对接研究
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-09 DOI: 10.2174/0109298673328877241113091539
Wei Li, Jing Huang, Zhixin Chen, Dan Zhang, Lin He, Yan Guo, Lei Zhong, Chenwu Yang, Chunyan Yang, Mei Zeng, Jiang Zhu, Zhongcheng Cao
{"title":"Design, Synthesis, Biological Evaluation and Docking Studies of 2-hydroxy-4-benzyloxy Chalcone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease.","authors":"Wei Li, Jing Huang, Zhixin Chen, Dan Zhang, Lin He, Yan Guo, Lei Zhong, Chenwu Yang, Chunyan Yang, Mei Zeng, Jiang Zhu, Zhongcheng Cao","doi":"10.2174/0109298673328877241113091539","DOIUrl":"https://doi.org/10.2174/0109298673328877241113091539","url":null,"abstract":"<p><strong>Objectives: </strong>Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, but no drugs can cure this disease. Chalcones possess good antioxidant activity, anti-neuroinflammatory activity, neuroprotective effects, inhibitory effects on Aβ aggregation, and Aβ disaggregation ability. Therefore, chalcones are ideal lead compounds, and the discovery of novel anti-AD agent-based chalcones is necessary.</p><p><strong>Methods: </strong>Hydroxy groups and aryl benzyl ether groups were introduced into chalcone scaffolds to obtain a series of 2-hydroxyl-4-benzyloxy chalcone derivatives. These derivatives were further synthesized, biologically evaluated, and docked.</p><p><strong>Results: </strong>Most target derivatives exhibited good anti-AD activities. In particular, compound 11d had excellent inhibitory effects on self-induced Aβ1-42 aggregation (90.8% inhibition rate at 25 μM) and Cu2+ induced Aβ1-42 aggregation (93.4% inhibition rate at 25 μM). In addition, it also exhibited good Aβ1-42 fibril disaggregation ability (64.7% at 25 μM), significant antioxidative activity (ORAC = 2.03 Trolox equivalent), moderate MAO-B inhibition (IC50 = 4.81 μM), selective metal chelation, appropriate BBB permeation, and dramatic anti-neuroinflammatory ability. In addition, compound 11d relieved AD symptoms and protected hippocampal neurons in vivo.</p><p><strong>Conclusion: </strong>Compound 11d is a promising multifunctional anti-Aβ agent.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural Modifications and Prospects of Histone Deacetylase (HDAC) Inhibitors in Cancer. 组蛋白去乙酰化酶(HDAC)抑制剂在癌症中的结构修饰与展望。
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-09 DOI: 10.2174/0109298673332285241104091609
Yu Chen, Jiahong Su, Sha Li, Feier Chen, Yan Zhang, Xingyue Wang, Yinping Zhang, Xiang Wang, Zijun Yuan, Siqi Ren, Xinyu He, Yueshui Zhao, Xu Wu, Mingxing Li, Fukuan Du, Shuai Deng, Jing Shen, Zhangang Xiao
{"title":"Structural Modifications and Prospects of Histone Deacetylase (HDAC) Inhibitors in Cancer.","authors":"Yu Chen, Jiahong Su, Sha Li, Feier Chen, Yan Zhang, Xingyue Wang, Yinping Zhang, Xiang Wang, Zijun Yuan, Siqi Ren, Xinyu He, Yueshui Zhao, Xu Wu, Mingxing Li, Fukuan Du, Shuai Deng, Jing Shen, Zhangang Xiao","doi":"10.2174/0109298673332285241104091609","DOIUrl":"https://doi.org/10.2174/0109298673332285241104091609","url":null,"abstract":"<p><p>Histone deacetylases (HDACs) play a crucial role in the regulation of cancer progression and have emerged as key targets for antitumor therapy. Histone Deacetylase Inhibitors (HDACis) effectively suppress tumor cell proliferation, induce apoptosis, and cause cell cycle arrest, demonstrating broad-spectrum antitumor activity. This article primarily focuses on enhancing the selectivity of HDACis through structural modification using natural compounds. It provides detailed insights into the structure modification of histone deacetylase 8 (HDAC8) and histone deacetylase 10 (HDAC10), as well as dual-- target inhibitors and their pharmacological effects. Furthermore, conventional HDAC inhibitors are susceptible to off-target effects and the development of drug resistance. Our research focuses on augmenting the targeting specificity of HDAC inhibitors through their combination with proteolysis targeting chimera (PROTAC). Lastly, the latest advancements in clinical research on HDAC inhibitors were summarized, revealing that these inhibitors possess limitations in their clinical applications due to intrinsic or acquired resistance. Consequently, this article primarily focuses on summarizing the current status and prospects of structural modifications for HDAC inhibitors, with the aim of inspiring researchers to develop novel HDAC inhibitors exhibiting enhanced activity for improved application in clinical research.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR+ Breast Cancer. FDA批准Inavolisib组合治疗pik3ca突变的HR+乳腺癌
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-08 DOI: 10.2174/0109298673365863250101070254
Jinwei Zhang
{"title":"FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR+ Breast Cancer.","authors":"Jinwei Zhang","doi":"10.2174/0109298673365863250101070254","DOIUrl":"https://doi.org/10.2174/0109298673365863250101070254","url":null,"abstract":"","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review on Branched-Chain Amino Acid Aminotransferase (BCAT) Inhibitors: Current Status, Challenges and Perspectives. 支链氨基酸转氨酶(BCAT)抑制剂的研究进展:现状、挑战与展望
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-08 DOI: 10.2174/0109298673320136241024054435
Xiansheng Zhang, Xinyuan Zhu, Yong Li, Yan Li, Wen Luo, Maaz Khan, Jiamin Pan, Hong Pan, Hua Xie, Guilong Zhao
{"title":"A Review on Branched-Chain Amino Acid Aminotransferase (BCAT) Inhibitors: Current Status, Challenges and Perspectives.","authors":"Xiansheng Zhang, Xinyuan Zhu, Yong Li, Yan Li, Wen Luo, Maaz Khan, Jiamin Pan, Hong Pan, Hua Xie, Guilong Zhao","doi":"10.2174/0109298673320136241024054435","DOIUrl":"https://doi.org/10.2174/0109298673320136241024054435","url":null,"abstract":"<p><p>Branched-chain amino acids (BCAAs) are essential amino acids for humans and play an indispensable role in many physiological and pathological processes. Branched-chain amino acid aminotransferase (BCAT) is a key enzyme that catalyzes the metabolism of BCAAs. BCAT is upregulated in many cancers and implicated in the development and progress of some other diseases, such as metabolic and neurological diseases; and therefore, targeting BCAT might be a potential therapeutic approach for these diseases. There are two isoforms of BCAT, i.e., cytoplasmic BCAT1 (or BCATc) and mitochondrial BCAT2 (or BCATm). The discovery of BCAT inhibitors was initiated by Warner-Lambert, a subsidiary of Pfizer, in 2000, followed by many other pharmaceutical companies, such as GlaxoSmithKline (GSK), Ergon, Icagen, Agios, and Bayer. Strategies of high-throughput screening (HTS), DNA-Encoded library technology (ELT), and fragment-based screening (FBS) have been employed for hit identification, followed by structural optimization. Despite low selectivity, both BCAT1 and BCAT2 selective inhibitors were individually developed, each with a few chemical structural classes. The most advanced BCAT1 inhibitor is BAY-069, discovered by Bayer, which has a potent enzymatic inhibitory activity against BCAT1 and a decent in vitro and in vivo pharmacokinetic profile but displayed weaker cellular inhibitory activity and almost no anti-proliferative activity. There are no BCAT inhibitors currently under investigation in clinical trials. Further studies are still needed to discover BCAT inhibitors with a more druggable profile for proof of concept. This review focuses on the latest progress of studies on the understanding of the physiology and pathology of BCAT and the discovery and development of BCAT inhibitors. The structure-activity relationship (SAR) and the druggability, and the challenges of BCAT inhibitors are discussed, with the aim of inspiring the discovery and development of BCAT inhibitors in the future.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA Modification and Digestive Tract Tumors: A Review. RNA修饰与消化道肿瘤研究进展。
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-08 DOI: 10.2174/0109298673350007241031025153
Yafeng Liu, Shujun Zhang, Kaijie Liu, Xinyu Gu, Xinjun Hu
{"title":"RNA Modification and Digestive Tract Tumors: A Review.","authors":"Yafeng Liu, Shujun Zhang, Kaijie Liu, Xinyu Gu, Xinjun Hu","doi":"10.2174/0109298673350007241031025153","DOIUrl":"https://doi.org/10.2174/0109298673350007241031025153","url":null,"abstract":"<p><p>Gastrointestinal tumors, including colorectal and liver cancer, are among the most prevalent and lethal solid tumors. These malignancies are characterized by worsening prognoses and increasing incidence rates. Traditional therapeutic approaches often prove ineffective. Recent advancements in high-throughput sequencing and sophisticated RNA modification detection technologies have uncovered numerous RNA chemical alterations significantly associated with the pathogenesis of various diseases, notably cancer. These discoveries have opened new avenues for therapeutic intervention. This article delves into epigenetic modifications, with a particular emphasis on RNA alterations such as N6-methyladenosine (m6A), 5-methylcytosine (m5C), 1-methyladenosine (m1A), 7-methylguanosine (m7G), and N4-acetylcysteine (ac4C). It examines the functions and mechanisms of action of regulatory entities known as \"Writers,\" \"Readers,\" and \"Erasers\" to these modifications. Additionally, it outlines various methodologies for detecting these RNA modifications. Conventional techniques include radioactive isotope incorporation, two-dimensional thin-layer chromatography (2D-TLC), mass spectrometry, and immunological detection methods. Specialized methods such as bisulfite sequencing and reverse transcription stops are also discussed. Furthermore, the article underscores the significance of these modifications in the development, progression, and therapeutic targeting of gastrointestinal tumors, including esophageal, gastric, colorectal, liver, and pancreatic cancers. This exploration provides foundational insights for enhancing diagnostic accuracy, treatment efficacy, and prognostic assessment in gastrointestinal oncology.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Effects of Tea Polyphenols on Renal Damage Induced by High Uric Acid. 茶多酚对高尿酸肾损害的治疗作用。
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-07 DOI: 10.2174/0109298673320456241024053452
Lingjuan Liu, Lanjun Shuai, Siyi He, Wei Xiang, Xiaojie He
{"title":"Therapeutic Effects of Tea Polyphenols on Renal Damage Induced by High Uric Acid.","authors":"Lingjuan Liu, Lanjun Shuai, Siyi He, Wei Xiang, Xiaojie He","doi":"10.2174/0109298673320456241024053452","DOIUrl":"https://doi.org/10.2174/0109298673320456241024053452","url":null,"abstract":"<p><strong>Background: </strong>Hyperuricemia (HUA) is a condition characterized by excessive uric acid production and/or inadequate uric acid excretion due to abnormal purine metabolism in the human body. Uric acid deposits resulting from HUA can lead to complications such as renal damage. Currently, drugs used to treat HUA lack specificity and often come with specific toxic side effects.</p><p><strong>Objective: </strong>This study aimed to investigate the renal protective effects of an optimized tea polyphenol formula and allopurinol in a rat model of hyperuricemia following renal resection. The goal was to explore the mechanisms underlying these effects.</p><p><strong>Methods: </strong>Initially, a blend was formulated based on the distinctive functions of catechins, thearubigins, tea polysaccharides, and theanine. Orthogonal experiments were then employed to select a rational combination. A 5/6 renal resection rat model was successfully established, and the animals were fed a 2% oxonic acid diet to induce hyperuricemia. Urinary protein content was measured using the biuret method, and serum levels of uric acid, creatinine, and urea nitrogen were determined biochemically. Kidney pathology was examined through HE staining and renal tubulointerstitial pathological scoring. The expression of α-SMA, CD34, PCNA, and TGF-β in renal tissue was detected using immunohistochemistry. Apoptosis of renal tubular epithelial cells was assessed using the TUNEL method.</p><p><strong>Results: </strong>Hyperuricemia markedly worsens renal damage in rats following nephrectomy, while tea polyphenols demonstrate the ability to reduce levels of blood uric acid, urea nitrogen, creatinine, and urinary protein. Additionally, tea polyphenols enhance smooth muscle proliferation in renal glomerular arterioles, prevent the loss of interstitial capillaries, alleviate apoptosis of renal tubular epithelial cells, promote their proliferation, and reduce interstitial fibrosis. A significant improvement in the severity of renal damage is observed in rats subjected to nephrectomy combined with hyperuricemia, and this effect surpasses that of allopurinol.</p><p><strong>Conclusion: </strong>Tea polyphenols could effectively alleviate renal damage in rats with nephrectomy combined with hyperuricemia. They demonstrate high cost-effectiveness and minimal side effects, positioning them as a promising new therapeutic option for hyperuricemia- induced renal damage.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CDK2 Allosteric Modulators: The New Route in the Design of New Drugs as Anticancer and Non-hormonal Contraceptives. CDK2变构调节剂:抗癌和非激素避孕药新药设计的新途径。
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-07 DOI: 10.2174/0109298673331207241019085108
Giulia Culletta, Anna Maria Almerico, Marco Tutone
{"title":"CDK2 Allosteric Modulators: The New Route in the Design of New Drugs as Anticancer and Non-hormonal Contraceptives.","authors":"Giulia Culletta, Anna Maria Almerico, Marco Tutone","doi":"10.2174/0109298673331207241019085108","DOIUrl":"https://doi.org/10.2174/0109298673331207241019085108","url":null,"abstract":"<p><p>CDK2 plays a pivotal role in controlling the cell cycle progression in eukaryotes and for this reason, it has been the subject of several studies for suitable inhibitors in the last decades. But more than 30 years of basic research have not generated an inhibitor as marketed drugs. Some inhibitors are to date in early phase clinical development. Moreover, most efforts to develop CDK2 inhibitors have been oriented towards orthosteric inhibitors, which block the kinase activity by binding to the ATP binding site, competing directly with ATP. These compounds have off-target kinase activity, because of the structural homology of the active sites of several other kinases. Targeting the CDK2 allosteric binding pocket could produce successful CDK2 inhibitors. Few examples of high-affinity allosteric CDK2 inhibitors are known. Despite promising research results, none has been approved for marketing. In recent years, various methodologies have been reported capable of identifying new and never-discovered portions of the target protein, which present adequate druggability characteristics. In this paper, we have highlighted and discussed the more recent findings on allosteric inhibitors intending to encouraging further exploration mainly focused on in silico drug discovery.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gold Nanoparticles and Chitosan as Innovative Compounds in Medicine and Cosmetology:A Review of Current Applications. 金纳米颗粒和壳聚糖在医学和美容中的应用综述。
IF 3.5 4区 医学
Current medicinal chemistry Pub Date : 2025-01-06 DOI: 10.2174/0109298673336929241004074529
Agata Kowalska, Agata Smułka, Elżbieta Adamska, Dorota Zarzeczańska, Tadeusz Ossowski, Beata Grobelna
{"title":"Gold Nanoparticles and Chitosan as Innovative Compounds in Medicine and Cosmetology:A Review of Current Applications.","authors":"Agata Kowalska, Agata Smułka, Elżbieta Adamska, Dorota Zarzeczańska, Tadeusz Ossowski, Beata Grobelna","doi":"10.2174/0109298673336929241004074529","DOIUrl":"https://doi.org/10.2174/0109298673336929241004074529","url":null,"abstract":"<p><p>The medical and cosmetic industries have developed in recent years, there has been a growing demand for new materials. Gold nanoparticles (Au NPs) and chitosan (CS) have been known and used for many years. Unfortunately, despite their numerous advantages and possible applications, such materials may possess certain disadvantages and limitations that constitute a problem in medical or cosmetic applications. Au NPs may have potential toxicity depending on their size, shape, charge, surface coatings, and tendency to agglomerate into larger clusters. On the other hand, the CS production process requires strict control due to the possibility of uncontrolled hydrolysis or chemical modifications during polymer isolation. The combination of Au NPs and CS that differ in chemical and phase in one composite (Au/CS) allows for acquiring of new material with many advantages. The obtained composite has good mechanical properties and is biocompatible due to the presence of CS and the antibacterial properties of Au NPs. Therefore, it can be successfully used in many branches of medicine, including gene delivery, cell encapsulation, wound healing process, or as a preservative ingredient of cosmetics. Moreover, Au/CS nanocomposites are used in the food industry and environmental protection. This review highlights the preparation routes, properties, and applications of Au NPs and CS as separate materials. Moreover, the last part presents the advantages of combining these two materials into one nanocomposite. Specifically, we described the role of CS in the synthesis of Au NPs and possible subsequent applications of such nanomaterials as an element of biosensors, scaffolds, and an intelligent drug release system or tissue engineering.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信